After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

For the first time in 20 years, the Food and Drug Administration has approved a new pharmaceutical approach to treating pain. On January 31, the FDA approved Journavx as ...

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

Most Advantage plans have a drug list, called a formulary. A person can check with their plan’s formulary to find out if Xarelto is covered. Medicare Part D covers prescription drugs.

DUBLIN--(BUSINESS WIRE)--The "Orphan Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Orphan Drugs was estimated at US$ ...

By every measure, that spending is on the rise; by drug “list price,” the increase is astronomical—from $636 billion in 2018 to $917 billion in 2023. What exactly are PBMs saving us from ...

C&EN’s tabulation follows approvals from the FDA’s Center for Drug Evaluation and Research; therefore, it does not include blood products, gene therapies, vaccines, and other therapies that ...

Clinical trials of the first drugs designed with the help of artificial intelligence could commence this year, Google DeepMind CEO Demis Hassabis suggested Tuesday. Speaking on a panel at the World ...

Geoffrey Joyce, the director of Health Policy at the University of Southern California's Schaeffer Center for Health Policy & Economics, told Newsweek that the $2 Medicare drug list model that ...

That report lists three proposed models: the Medicare High-Value Drug List Model, the Cell & Gene Therapy Access Model and the Accelerating Clinical Evidence Model. The first model allows Part D ...